Home > Clinical Trials

Saved trials

TERMINATED
NCT05954143
Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
11 Enrollment(s)
4 Study location(s)
INTERVENTIONAL (PHASE2)
Metastatic Breast Cancer


HER2-positive Breast Cancer
ACTIVE_NOT_RECRUITING
NCT05704829
NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer
402 Enrollment(s)
43 Study location(s)
INTERVENTIONAL (PHASE2)
HER2-positive Early Breast Cancer
RECRUITING
NCT04986579
Scalp Cooling in MBC
120 Enrollment(s)
2 Study location(s)
INTERVENTIONAL (PHASE2)
Metastatic Breast Cancer


Chemotherapy-induced Alopecia
ACTIVE_NOT_RECRUITING
NCT04618913
Anticoagulation in Patients With Venous Thromboembolism and Cancer
1 Enrollment(s)
1 Study location(s)
OBSERVATIONAL (None)
Neoplasms


Embolism
RECRUITING
NCT07180264
Trastuzumab Deruxtecan in Advanced Breast Cancer
118 Enrollment(s)
1 Study location(s)
OBSERVATIONAL (None)
Advanced Breast Cancer
COMPLETED
NCT06961331
Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.
93 Enrollment(s)
1 Study location(s)
OBSERVATIONAL (None)
Metastatic HER2+ Advanced Breast Cancer
ACTIVE_NOT_RECRUITING
NCT05113251
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
927 Enrollment(s)
146 Study location(s)
INTERVENTIONAL (PHASE3)
Breast Neoplasms


Breast Cancer


HER2-positive Early Breast Cancer
ACTIVE_NOT_RECRUITING
NCT04042701
DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer
115 Enrollment(s)
30 Study location(s)
INTERVENTIONAL (PHASE1)
Breast Cancer


Non-small Cell Lung Carcinoma